Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 9, 2018
Mustang Bio to Present at 10th Annual Bioprocessing Summit
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
August 9, 2018
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK, Aug. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) ...
August 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
August 9, 2018
Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis
PITTSBURGH, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering ...
August 9, 2018
HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited
TUCSON, Ariz., Aug. 09, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today ...
August 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
August 9, 2018
PolarityTE, Inc. Announces the Addition of Ramses Erdtmann, Managing Partner at Point Sur Investors and Former Executive at Pharmacyclics, and David Seaburg, Managing Director at Cowen and CNBC Contributor, to the Board of Directors
SALT LAKE CITY, Aug. 09, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
August 9, 2018
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
BUFFALO, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ...
August 9, 2018
Vaccinex Announces Pricing of Initial Public Offering
ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to ...
August 9, 2018
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
August 6, 2018
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and ...
August 6, 2018
Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
August 6, 2018
Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, ...
August 6, 2018
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
PALO ALTO, Calif., Aug. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced ...
August 6, 2018
STRATA Skin Sciences Announces FDA Granted 510(k) Clearance for the Multi Micro Dose™ Tip for its XTRAC® 308nm Excimer Laser
HORSHAM, Pa., Aug. 06, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
August 6, 2018
Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update
PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (KRYS), a gene therapy company advancing  “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported ...
August 6, 2018
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology ...
August 3, 2018
CMS Grants New Technology Add-on Payment to ZEMDRI™ (plazomicin)
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
August 3, 2018
Athenex, Inc. to Report Second Quarter Earnings Results on August 14, 2018
BUFFALO, N.Y., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
August 3, 2018
HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development
TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications ...
Page 24 of 117